- Home
- JELD vs MOLN Comparison
JELD vs MOLN Comparison
Compare JELD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JELD | MOLN |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Forest Products | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 144.0M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JELD | MOLN |
|---|---|---|
| Price | $1.47 | $3.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.43 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 1.7M | 1.8K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $3.41 |
| 52 Week High | $6.98 | $5.36 |
Technical Indicators
Market Signals| Indicator | JELD | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 32.97 |
| Support Level | $1.25 | $3.52 |
| Resistance Level | $2.06 | $3.97 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 38.39 | 3.70 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.